Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954

Official URL:https://doi.org/10.1200/JCO.2009.26.6114
PubMed:View item in PubMed
Creators Name:Schuhmacher, C. and Gretschel, S. and Lordick, F. and Reichardt, P. and Hohenberger, W. and Eisenberger, C.F. and Haag, C. and Mauer, M.E. and Hasan, B. and Welch, J. and Ott, K. and Hoelscher, A. and Schneider, P.M. and Bechstein, W. and Wilke, H. and Lutz, M.P. and Nordlinger, B. and Van Cutsem, E. and Siewert, J.R. and Schlag, P.M.
Journal Title:Journal of Clinical Oncology
Journal Abbreviation:J Clin Oncol
Volume:28
Number:35
Page Range:5210-5218
Date:10 December 2010
Keywords:Adenocarcinoma, Antineoplastic Agents, Cardia, Combined Modality Therapy, Digestive System Surgical Procedures, Disease-Free Survival, Esophagogastric Junction, Kaplan-Meier Estimate, Neoadjuvant Therapy, Neoplasm Staging, Stomach Neoplasms
Abstract:PURPOSE Patients with locally advanced gastric cancer benefit from combined pre- and postoperative chemotherapy, although fewer than 50% could receive postoperative chemotherapy. We examined the value of purely preoperative chemotherapy in a phase III trial with strict preoperative staging and surgical resection guidelines. PATIENTS AND METHODS Patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEG II and III) were randomly assigned to preoperative chemotherapy followed by surgery or to surgery alone. To detect with 80% power an improvement in median survival from 17 months with surgery alone to 24 months with neoadjuvant, 282 events were required. Results This trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III. The International Union Against Cancer R0 resection rate was 81.9% after neoadjuvant chemotherapy as compared with 66.7% with surgery alone (P = .036). The surgery-only group had more lymph node metastases than the neoadjuvant group (76.5% v 61.4%; P = .018). Postoperative complications were more frequent in the neoadjuvant arm (27.1% v 16.2%; P = .09). After a median follow-up of 4.4 years and 67 deaths, a survival benefit could not be shown (hazard ratio, 0.84; 95% CI, 0.52 to 1.35; P = .466). CONCLUSION This trial showed a significantly increased R0 resection rate but failed to demonstrate a survival benefit. Possible explanations are low statistical power, a high rate of proximal gastric cancer including AEG and/or a better outcome than expected after radical surgery alone due to the high quality of surgery with resections of regional lymph nodes outside the perigastic area (celiac trunc, hepatic ligament, lymph node at a. lienalis; D2).
ISSN:0732-183X
Publisher:American Society of Clinical Oncology (U.S.A.)
Item Type:Article

Repository Staff Only: item control page

Open Access
MDC Library